PATIENT DERIVED XENOGRAFT MODEL MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Patient Derived Xenograft Model Market, By Model Type (Cell line derived models, Patient derived organoids, Genetically engineered models and Others (Primary cell derived models, cell processed models etc.)), By Implantation Method (Subcutaneous Implantation, Orthopedic Implantation and Others), By Tumor Type (Blood Cancer Models, Solid Tumor Models, Pediatric Tumor Models, Other Rare Tumor Models, Combination PDX Models, Custom PDX Models, Others), By Application (Gastrointestinal Tumor Model, Gynecological Tumor Model, Respiratory Tumor Model and Other Tumor Model), By End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Academic & Research Institutions, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Nov 2023
Code : CMI6506
Pages :140
Formats :
Excel and PDF
Industry : Biotechnology

Patient Derived Xenograft Model Market Size and Trends

The Patient Derived Xenograft Model Market size is expected to reach US$ 346 million by 2030, from US$ 105.4 million in 2023, at a CAGR of 18.5% during the forecast period. Patient-derived xenograft (PDX) models are developed by implanting patient tumor samples into immunodeficient mice. These models retain the principal histopathological and genetic characteristics of their originating tumors and are emerging as a clinically relevant cancer model for cancer research and precision medicines. The increasing use of PDX models in preclinical oncology research and personalized medicine is a major factor driving the market growth.

Figure 2. Global Patient Derived Xenograft Model Market Share (%), by Model Type, 2023

Patient Derived Xenograft Model Market Trends:

Integration with OMICs Technologies: The pairing of PDX models with genomic, transcriptomic and proteomic profiling technologies is enabling in-depth molecular characterization and biomarker discovery. Companies like Crown Bioscience and Champions Oncology offer integrated PDX-OMICs platforms combining drug efficacy testing with multi-omics analysis on PDX models. The development of PDX biobanks with comprehensive omics datasets will facilitate biomarker validation and personalized therapy development.
Consortium-based PDX Model Development: Oncology researchers are collaborating to build large PDX collections through consortiums representing multiple cancer types. The EurOPDX, Paediatric Preclinical Proof of Concept platform, and PRISM PDX Development Consortium are examples of collaborative PDX networks expanding model access for academia and industry. The collective approach to PDX generation leverages expertise across research centers and enhances standardization.
Development of Next-generation PDX Technologies: Emerging PDX technologies, such as 3D-bioprinted tumor models and organoid-PDX hybrids, are garnering interest from cancer researchers. For instance, the HuPrime PDX model developed by Horizon Discovery enables co-engraftment of human stromal components along with patient tumors. Adoption of novel techniques to improve engraftment, personalized relevance, and molecular fidelity of PDX models will support market growth.